keyword
MENU ▼
Read by QxMD icon Read
search

"Hepatitis c" cost

keyword
https://www.readbyqxmd.com/read/28221274/pharmacy-use-in-the-first-year-of-the-veterans-choice-program-a-mixed-methods-evaluation
#1
Walid F Gellad, Francesca E Cunningham, Chester B Good, Joshua M Thorpe, Carolyn T Thorpe, Brandi Bair, KatieLynn Roman, Susan L Zickmund
BACKGROUND: The Veterans Choice Program (VCP) was created to ensure timely access to health care in the Department of Veterans Affairs (VA). Under this program, medications may be ordered by select non-VA clinicians to be dispensed by VA pharmacies, creating new challenges in ensuring medication safety. OBJECTIVES: To examine pharmaceutical use during the first year of the VCP and to understand barriers and facilitators for VA pharmacists to dispensing medications under the VCP...
February 17, 2017: Medical Care
https://www.readbyqxmd.com/read/28219761/development-and-validation-of-a-real-time-reverse-transcription-pcr-assay-for-rapid-and-low-cost-genotyping-of-hepatitis-c-virus-genotypes-1a-1b-2-and-3a
#2
Andrea D Olmstead, Tracy D Lee, Ron Chow, Kingsley Gunadasa, Brian Auk, Mel Krajden, Agatha N Jassem
Hepatitis C virus (HCV) infection affects millions of people and leads to liver fibrosis, cirrhosis, and hepatocellular carcinoma. Treatment regimen selection requires HCV genotype (Gt) and Gt 1 subtype determination. Use of a laboratory developed, reverse transcription (RT)-PCR assay was explored as a low-cost, high-throughput screening approach for the major HCV genotypes and subtypes in North America. A commercial line probe assay (LiPA) was used for comparison. Sequencing and/or an alternative PCR assay were used for discordant analyses...
February 17, 2017: Journal of Virological Methods
https://www.readbyqxmd.com/read/28218867/-screening-diagnosis-treatment-and-follow-up-of-hepatitis-c-virus-related-liver-disease-national-consensus-guideline-in-hungary-from-15-october-2016
#3
Béla Hunyady, Zsuzsanna Gerlei, Judit Gervain, Gábor Horváth, Gabriella Lengyel, Alajos Pár, Zoltán Péter, László Rókusz, Ferenc Schneider, Ferenc Szalay, István Tornai, Klára Werling, Mihály Makara
Treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary. This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents. Indication of therapy in patients with no contraindication is based on demonstration of viral replication with consequent inflammation and/or fibrosis in the liver...
February 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28214902/impact-of-renal-disease-on-patients-with-hepatitis-c-a-retrospective-analysis-of-disease-burden-clinical-outcomes-and-health-care-utilization-and-cost
#4
Craig A Solid, Senaka A Peter, Tanya Natwick, Haifeng Guo, Allan J Collins, Jean Marie Arduino
BACKGROUND/AIMS: Few studies explore the magnitude of the disease burden and health care utilization imposed by renal disease among patients with hepatitis C virus (HCV). We aimed to describe the characteristics, outcomes, and health care utilization and costs of patients with HCV with and without renal impairment. METHODS: This retrospective analysis used 2 administrative claims databases: the US commercially insured population in Truven Health MarketScan® data (aged 20-64 years), and the US Medicare fee-for-service population in the Medicare 20% sample (aged ≥65 years)...
February 18, 2017: Nephron
https://www.readbyqxmd.com/read/28209492/reproductive-considerations-in-the-setting-of-chronic-viral-illness
#5
REVIEW
Brent M Hanson, Jessie A Dorais
Special considerations must be taken when patients with human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C desire to achieve pregnancy. Patients with chronic viral illnesses desire children at rates similar to the general population, and options are available to decrease both vertical transmission and viral transmission between partners. Preconception counseling or consultation with fertility specialists is imperative in patients with HIV, Hepatitis B, and Hepatitis C so that reproductive goals can be addressed and optimized...
February 13, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28207300/single-nucleotide-rs760370-polymorphism-at-the-main-ribavirin-transporter-gene-detection-by-pcr-rflp-assay-compared-with-the-taqman-assay-and-its-relation-to-sustained-virological-response-in-chronic-hcv-patients-treated-with-pegylated-interferon-ribavirin
#6
Rabab Fouad, Khaled Zachariah, Marwa Khairy, Mervat Khorshied, Wafaa Ezzat, Marwa M Sheta, Ahmed Heiba
Ribavirin clearly plays a role in chronic hepatitis C treatment response. The equilibrative nucleoside transporter-1 codified by SLC29A1 gene has been associated with ribavirin uptake into hepatocytes and erythrocytes. rs760370A>G single nucleotide polymorphism (SNP) at the SLC29A1 gene may have a role in ribavirin-based regimen treatment response. Accuracy of the polymerase-chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay compared with the TaqMan assay for the detection of the SNP rs760370 at the main ribavirin transporter gene and its relation to sustained virological response in chronic hepatitis C virus (HCV) patients treated with pegylated interferon-ribavirin therapy...
February 2017: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/28203449/a-cost-utility-analysis-of-different-antiviral-medicine-regimens-in-patients-with-chronic-hepatitis-c-virus-genotype-1-infection
#7
Seyed Moayed Alavian, Shekoufeh Nikfar, Abbas Kebriaeezadeh, Farhad Lotfi, Ehsan Sanati, Mohsen Rezaei Hemami, Khosro Keshavarz
BACKGROUND: Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, especially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been conducted yet. OBJECTIVES: This study is aimed to assess the cost-effectiveness of the three drug regimens of pegylated interferon and ribavirin (PR), sofosbuvir (SOF) + PR and ledipasvir and sofosbuvir (LDV/SOF) in patients with HCV genotype 1 in Iran in the year 2014...
November 2016: Iranian Red Crescent Medical Journal
https://www.readbyqxmd.com/read/28202839/cost-outcome-description-of-peg-ifn-%C3%AE-2b-rbv-for-hepatitis-c-results-based-on-the-interferon-database
#8
Maiko Akutagawa, Yohei Kawasaki, Atsuko Kawasaki, Kazuki Ide, Hiroshi Yamada, Naohiko Masaki
Economic evaluation of drugs is used in decision-making on medical care and public policy. Recently, real-world data (RWD) have been used in the analysis. In this study, we discuss the risk and benefits of using RWD for economic evaluation. We conducted a cost-outcome description with RWD from a nationwide registry providing information on hepatitis treatment in Japan and estimated the utility of the analysis. We evaluated the cost-outcome description of peginterferon plus ribavirin (PEG-IFN-α2b + RBV) treatment in hepatitis C virus (HCV)-infected patients...
February 15, 2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28199776/understanding-patient-perceptions-and-risk-for-hepatitis-c-screening
#9
Sheriedan Grannan
OBJECTIVES: The specific aims were to identify specific themes and barriers to HCV testing and to determine if testing rates increased when patients self-identify their risk factors and were offered testing. SETTING: The study was conducted at a Federally Qualified Health Center (FQHC) in an underserved neighborhood located in the Mountain West. METHODS: This descriptive study used survey and group-level electronic health record (EHR) data...
February 15, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28193102/identification-of-predictors-for-treatment-failure-in-hepatitis-c-virus-patients-treated-with-ledipasvir-and-sofosbuvir
#10
Jeffrey W Jansen, Gillian M Powderly, Travis W Linneman
BACKGROUND: New hepatitis C virus (HCV) therapies report cure rates of ~90% but are expensive. Identification of predictors for treatment failure could help decrease health care costs, limit unnecessary drug exposure and adverse events, and prevent drug-drug interactions. Failure to achieve rapid viral response (RVR), defined as detectable viral load at 4 weeks, has previously been identified as a predictor of treatment failure with some previous HCV therapies. OBJECTIVE: To evaluate RVR, and other potential variables, as predictors of treatment failure in patients treated with ledipasvir and sofosbuvir (LDV/SOF)...
February 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28174263/quantifying-antiviral-activity-optimizes-drug-combinations-against-hepatitis-c-virus-infection
#11
Yoshiki Koizumi, Hirofumi Ohashi, Syo Nakajima, Yasuhito Tanaka, Takaji Wakita, Alan S Perelson, Shingo Iwami, Koichi Watashi
With the introduction of direct-acting antivirals (DAAs), treatment against hepatitis C virus (HCV) has significantly improved. To manage and control this worldwide infectious disease better, the "best" multidrug treatment is demanded based on scientific evidence. However, there is no method available that systematically quantifies and compares the antiviral efficacy and drug-resistance profiles of drug combinations. Based on experimental anti-HCV profiles in a cell culture system, we quantified the instantaneous inhibitory potential (IIP), which is the logarithm of the reduction in viral replication events, for both single drugs and multiple-drug combinations...
February 7, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28173785/hcv-screening-in-a-cohort-of-hiv-infected-and-uninfected-homeless-and-marginally-housed-women-in-san-francisco-california
#12
Kimberly Page, Michelle Yu, Jennifer Cohen, Jennifer Evans, Martha Shumway, Elise D Riley
BACKGROUND: Hepatitis C virus (HCV) screening has taken on new importance as a result of updated guidelines and new curative therapies. Relatively few studies have assessed HCV infection in homeless populations, and a minority include women. We assessed prevalence and correlates of HCV exposure in a cohort of homeless and unstably housed women in San Francisco, and estimated the proportion undiagnosed. METHODS: A probability sample of 246 women were recruited at free meal programs, homeless shelters, and low-cost single room occupancy hotels in San Francisco; women with HIV were oversampled...
February 7, 2017: BMC Public Health
https://www.readbyqxmd.com/read/28170123/martinello-et%C3%A2-al-hcv-reinfection-incidence-among-individuals-treated-for-recent-infection
#13
Patrick Ingiliz
The development of all-oral direct-acting antiviral agents (DAA) has changed the management of patients infected with the hepatitis C virus (HCV). As these new treatments are safe and highly effective, most affected patients may have a chance for HCV cure, at least in those parts of the world where the costly drugs available. In industrialized countries, HCV infection has a comparatively low prevalence in the general population(1) . A higher prevalence and new infections are mainly seen in two specific subgroups: people who inject drugs (PWID) and HIV-positive men who have sex with men (MSM)...
February 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28164720/applications-of-computer-aided-approaches-in-the-development-of-hepatitis-c-antiviral-agents
#14
Aravindhan Ganesan, Khaled Barakat
Hepatitis C virus (HCV) is a global health problem that causes several chronic life-threatening liver diseases. The numbers of people affected by HCV are rising annually. Since 2011, the FDA has approved several anti-HCV drugs; while many other promising HCV drugs are currently in late clinical trials. Areas covered: This review discusses the applications of different computational approaches in HCV drug design. Expert opinion: Molecular docking and virtual screening approaches have emerged as a low-cost tool to screen large databases and identify potential small-molecule hits against HCV targets...
February 4, 2017: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/28148799/computational-prediction-of-the-heterodimeric-and-higher-order-structure-of-gpe1-gpe2-envelope-glycoproteins-encoded-by-the-hepatitis-c-virus-hcv
#15
Holly Freedman, Michael R Logan, Darren Hockman, Julia Koehler Leman, John Lok Man Law, Michael Houghton
: Despite the recent success of newly developed direct acting antivirals against Hepatitis C, the disease continues to be a global health threat due to lack of diagnosis of most carriers and the high cost of treatment. The heterodimer formed by the glycoproteins E1 and E2 within the hepatitis C virus (HCV) lipid envelope is a potential vaccine candidate and antiviral target. While the structure of E1/E2 has not yet been resolved, partial crystal structures of the E1 and E2 ectodomains have been determined...
February 1, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28144454/role-of-il28-b-polymorphism-rs12979860-on-sustained-virological-response-to-pegylated-interferon-ribavirin-in-iranian-patients-with-chronic-hepatitis-c
#16
Mahtab Daneshvar, Mehri Nikbin, Solmaz Talebi, Foozieh Javadi, Mohammad Reza Aghasadeghi, Sanaz Mahmazi, Seyed Mehdi Sadat
BACKGROUND: The current medical treatment for hepatitis C virus (HCV) infection is pegylated interferon plus ribavirin, but just 50% of genotype 1 HCV patients and about 80% of HCV genotype 3 patients are treated completely. Recently, the rs12979860 C/T polymorphism, which is located 3 kb upstream of the IL28b gene that codes IFNλ3, shows a powerful association in response to the treatment in HCV patients. OBJECTIVES: The aim of this study was to evaluate the relationship between IL28b single nucleotide polymorphism (SNP) and treatment outcomes among chronic HCV patients in Iran...
September 2016: Iranian Red Crescent Medical Journal
https://www.readbyqxmd.com/read/28139384/comorbidity-effects-on-shoulder-arthroplasty-costs-analysis-of-a-nationwide-private-payer-insurance-data-set
#17
Samuel Rosas, Karim G Sabeh, Leonard T Buller, Tsun Yee Law, Steven P Kalandiak, Jonathan C Levy
BACKGROUND: The purpose of this study was to evaluate the effect of common medical comorbidities on the reimbursements of different shoulder arthroplasty procedures. METHODS: We conducted a retrospective query of a single private payer insurance claims database using PearlDiver (Warsaw, IN, USA) from 2010 to 2014. Our search included the Current Procedural Terminology codes and International Classification of Diseases, Ninth Revision codes for total shoulder arthroplasty (TSA), hemiarthroplasty, and reverse shoulder arthroplasty (RSA)...
January 27, 2017: Journal of Shoulder and Elbow Surgery
https://www.readbyqxmd.com/read/28128648/clinical-characteristics-healthcare-costs-and-resource-utilization-in-hepatitis-c-vary-by-genotype
#18
Alyssa Goolsby Hunter, Lisa Rosenblatt, Chad Patel, Cori Blauer-Peterson, Beatrice Anduze-Faris
BACKGROUND: In the United States, approximately 3 million people are infected with hepatitis C virus (HCV). Genotypes of HCV variably affect disease progression and treatment response. However, the relationships between HCV genotypes and liver disease progression, healthcare resource utilization, and healthcare costs have not been fully explored. RESEARCH DESIGN AND METHODS: In this retrospective study of patients with chronic hepatitis C (CHC), healthcare claims from a large US health plan were used to collect data on patient demographic and clinical characteristics...
January 27, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28124463/hepatitis-c-treatment-from-response-guided-to-resource-guided-therapy-in-the-transition-era-from-ifn-containing-to-ifn-free-regimens
#19
REVIEW
Ming-Lung Yu
Peginterferon/ribavirin has been the standard-of-care for chronic hepatitis C virus (HCV) infections: 48-week for genotype 1 or 4 (HCV-1/4) and 24-week for HCV-2/3. Response-guided therapy recommended shorter 24-week and 16-week regimens for HCV-1 with lower baseline viral loads (LVL, <400,000-800,000 IU/ml) and rapid virological response (RVR, undetectable HCV RNA at week 4) and HCV-2/3 with RVR, respectively; and extending to 72 and 48 weeks for HCV-1 slower responders and HCV-2 non-RVR patients, respectively, to improve the efficacy...
January 26, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28097100/hepatitis-c-virus-a-review-of-treatment-guidelines-cost-effectiveness-and-access-to-therapy
#20
REVIEW
Shaina M Lynch, George Y Wu
Hepatitis C virus (HCV) infection remains a significant medical concern in the United States and around the world. It is still one of the leading causes of chronic liver disease, and, for more than 20 years, there has been little progress in the treatment of HCV infection. The advent of direct-acting antivirals (DAAs) initiated the era of high efficacy and well-tolerated medications with high cure rates. The efficacy of these medications has prompted many professional societies around the world to update their treatment guidelines to include DAAs as first-line treatment...
December 28, 2016: Journal of Clinical and Translational Hepatology
keyword
keyword
90225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"